Profiel
Hartmut J.
Ehrlich is currently the Chief Executive Officer at Wittycell SAS and Director at Spikimm SAS.
Previously, he was the Chief Executive Officer at Abivax SA from 2013 to 2023 and Head-Global Research & Development at Baxter International, Inc. from 2006 to 2013.
Actieve functies van Hartmut Ehrlich
| Bedrijven | Functie | Begin |
|---|---|---|
Wittycell SAS
 Wittycell SAS Pharmaceuticals: MajorHealth Technology Wittycell SAS engages in the research and development, manufacturing, and sale of therapeutic and prophylactic vaccines. It offers novel adjuvant products against infectious diseases and cancer. The company was founded in August 2005 and is headquartered in Reims, France. | Chief Executive Officer | - |
| Spikimm SAS | Director/Board Member | - |
Eerdere bekende functies van Hartmut Ehrlich
| Bedrijven | Functie | Einde |
|---|---|---|
| ABIVAX | Chief Executive Officer | 05-05-2023 |
| BAXTER INTERNATIONAL INC. | Chief Tech/Sci/R&D Officer | 01-09-2013 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| ABIVAX | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Wittycell SAS
Wittycell SAS Pharmaceuticals: MajorHealth Technology Wittycell SAS engages in the research and development, manufacturing, and sale of therapeutic and prophylactic vaccines. It offers novel adjuvant products against infectious diseases and cancer. The company was founded in August 2005 and is headquartered in Reims, France. | Health Technology |
| Spikimm SAS |
